These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 33309485

  • 1. Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.
    Zacharia A, Harberts E, Valencia SM, Myers B, Sanders C, Jain A, Larson NR, Middaugh CR, Picking WD, Difilippantonio S, Kirnbauer R, Roden RB, Pinto LA, Shoemaker RH, Ernst RK, Marshall JD.
    Vaccine; 2021 Jan 08; 39(2):292-302. PubMed ID: 33309485
    [Abstract] [Full Text] [Related]

  • 2. Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.
    Valencia SM, Zacharia A, Marin A, Matthews RL, Wu CK, Myers B, Sanders C, Difilippantonio S, Kirnbauer R, Roden RB, Pinto LA, Shoemaker RH, Andrianov AK, Marshall JD.
    Hum Vaccin Immunother; 2021 Aug 03; 17(8):2748-2761. PubMed ID: 33573433
    [Abstract] [Full Text] [Related]

  • 3. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R.
    PLoS One; 2017 Aug 03; 12(1):e0169533. PubMed ID: 28056100
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
    Ahmels M, Mariz FC, Braspenning-Wesch I, Stephan S, Huber B, Schmidt G, Cao R, Müller M, Kirnbauer R, Rösl F, Hasche D.
    Front Immunol; 2022 Jul 15; 13():1010790. PubMed ID: 36263027
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 10. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND.
    Vaccine; 2015 Oct 13; 33(42):5553-5563. PubMed ID: 26382603
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B, Schellenbacher C, Jindra C, Fink D, Shafti-Keramat S, Kirnbauer R.
    PLoS One; 2015 Oct 13; 10(3):e0120152. PubMed ID: 25790098
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
    Schellenbacher C, Roden R, Kirnbauer R.
    J Virol; 2009 Oct 13; 83(19):10085-95. PubMed ID: 19640991
    [Abstract] [Full Text] [Related]

  • 18. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
    Seitz H, Canali E, Ribeiro-Müller L, Pàlfi A, Bolchi A, Tommasino M, Ottonello S, Müller M.
    Vaccine; 2014 May 07; 32(22):2610-7. PubMed ID: 24662712
    [Abstract] [Full Text] [Related]

  • 19. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K, Chivukula S, Tibbitts T, Yan Y, Stegalkina S, Shen L, Cieszynski J, Costa V, Sabharwal R, Anderson SF, Christensen N, Jagu S, Roden RBS, Kleanthous H.
    Vaccine; 2017 Sep 05; 35(37):4942-4951. PubMed ID: 28778613
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.